189 related articles for article (PubMed ID: 24857398)
1. Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.
Ruiz-DeDiego I; Mellstrom B; Vallejo M; Naranjo JR; Moratalla R
Biol Psychiatry; 2015 Jan; 77(2):95-105. PubMed ID: 24857398
[TBL] [Abstract][Full Text] [Related]
2. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
[TBL] [Abstract][Full Text] [Related]
3. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Pavón N; Martín AB; Mendialdua A; Moratalla R
Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
[TBL] [Abstract][Full Text] [Related]
4. Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Cenci MA
Amino Acids; 2002; 23(1-3):105-9. PubMed ID: 12373525
[TBL] [Abstract][Full Text] [Related]
5. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
[TBL] [Abstract][Full Text] [Related]
7. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
[TBL] [Abstract][Full Text] [Related]
8. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Ravenscroft P; Chalon S; Brotchie JM; Crossman AR
Exp Neurol; 2004 Jan; 185(1):36-46. PubMed ID: 14697317
[TBL] [Abstract][Full Text] [Related]
9. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
[TBL] [Abstract][Full Text] [Related]
10. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
Lundblad M; Vaudano E; Cenci MA
J Neurochem; 2003 Mar; 84(6):1398-410. PubMed ID: 12614340
[TBL] [Abstract][Full Text] [Related]
11. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
Winkler C; Kirik D; Björklund A; Cenci MA
Neurobiol Dis; 2002 Jul; 10(2):165-86. PubMed ID: 12127155
[TBL] [Abstract][Full Text] [Related]
12. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
[TBL] [Abstract][Full Text] [Related]
13. Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.
Lane EL; Vercammen L; Cenci MA; Brundin P
Exp Neurol; 2009 Sep; 219(1):355-8. PubMed ID: 19393238
[TBL] [Abstract][Full Text] [Related]
14. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Damier P; Tremblay L; Féger J; Hirsch EC
Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
[TBL] [Abstract][Full Text] [Related]
15. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
[TBL] [Abstract][Full Text] [Related]
16. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
Lindgren HS; Ohlin KE; Cenci MA
Neuropsychopharmacology; 2009 Nov; 34(12):2477-88. PubMed ID: 19606087
[TBL] [Abstract][Full Text] [Related]
17. L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice.
Santini E; Alcacer C; Cacciatore S; Heiman M; Hervé D; Greengard P; Girault JA; Valjent E; Fisone G
J Neurochem; 2009 Feb; 108(3):621-33. PubMed ID: 19187092
[TBL] [Abstract][Full Text] [Related]
18. The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
Lindenbach D; Conti MM; Ostock CY; George JA; Goldenberg AA; Melikhov-Sosin M; Nuss EE; Bishop C
J Neurosci; 2016 Sep; 36(38):9873-87. PubMed ID: 27656025
[TBL] [Abstract][Full Text] [Related]
19. Downstream regulatory element antagonistic modulator regulates islet prodynorphin expression.
Jacobson DA; Cho J; Landa LR; Tamarina NA; Roe MW; Buxbaum JD; Philipson LH
Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E587-95. PubMed ID: 16621893
[TBL] [Abstract][Full Text] [Related]
20. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
